Methods and agents for treating acute neuroinflammatory injury
AssigneeImplicit Bioscience Limited
InventorsBrian W. Ziegelaar, David T. Crowe, Garry Llewellyn Redlich
Life of this patent
Estimating the term…
Abstract
This disclosure relates generally to methods and agents for treating acute neuroinflammatory injury, such as stroke (e.g. ischemic stroke or hemorrhagic stroke), hypoxic-ischemic brain injury, traumatic brain injury, subarachnoid hemorrhage and intracerebral hemorrhage. In particular, the present disclosure relates to the use of CD14 antagonist antibodies for treating acute neuroinflammatory injury.
Claims16
A method for treating stroke in a human subject, comprising, consisting or consisting essentially of administering an effective amount of a CD14 antagonist antibody to the subject, wherein the antibody is administered to the subject up to 48 hours post-injury.
A method for treating stroke in a human subject, comprising, consisting or consisting essentially of systemically administering an effective amount of a CD14 antagonist antibody to the subject, wherein the antibody is administered alone.
A method for treating stroke in a human subject, comprising, consisting or consisting essentially of administering an effective amount of a CD14 antagonist antibody to the subject, wherein the antibody is administered as a single dose.
A method of treating stroke in a human subject, comprising, consisting or consisting essentially of administering an effective amount of a CD14 antagonist antibody to the subject, wherein the CD14 antagonist antibody is selected from:
- (i) an antibody that comprises:
- a) an antibody VL domain, or antigen binding fragment thereof, comprising L-CDR1, L-CDR2 and L-CDR3, wherein:
- L-CDR1 comprises the sequence RASESVDSFGNSFMH [SEQ ID NO:
- 7] (3C10 L-CDR1);
- L-CDR2 comprises the sequence RAANLES [SEQ ID NO:
- 8] (3C10 L-CDR2);
- and L-CDR3 comprises the sequence QQSYEDPWT [SEQ ID NO:
- 9] (3C10 L-CDR3);
- and b) an antibody VH domain, or antigen binding fragment thereof, comprising H-CDR1, H-CDR2 and H-CDR3, wherein:
- H-CDR1 comprises the sequence SYAMS [SEQ ID NO:
- 10] (3C10 H-CDR1);
- H-CDR2 comprises the sequence SISSGGTTYYPDNVKG [SEQ ID NO:
- 11] (3C10 H-CDR2);
- and H-CDR3 comprises the sequence GYYDYHY [SEQ ID NO:
- 12] (3C10 H-CDR3);
- (ii) an antibody that comprises:
- a) an antibody VL domain, or antigen binding fragment thereof, comprising L-CDR1, L-CDR2 and L-CDR3, wherein:
- L-CDR1 comprises the sequence RASESVDSYVNSFLH [SEQ ID NO:
- 13] (28C5 L-CDR1);
- L-CDR2 comprises the sequence RASNLQS [SEQ ID NO:
- 14] (28C5 L-CDR2);
- and L-CDR3 comprises the sequence QQSNEDPTT [SEQ ID NO:
- 15] (28C5 L-CDR3);
- and b) an antibody VH domain, or antigen binding fragment thereof, comprising H-CDR1, H-CDR2 and H-CDR3, wherein:
- H-CDR1 comprises the sequence SDSAWN [SEQ ID NO:
- 16] (28C5 H-CDR1);
- H-CDR2 comprises the sequence YISYSGSTSYNPSLKS [SEQ ID NO:
- 17] (28C5 H-CDR2);
- and H-CDR3 comprises the sequence GLRFAY [SEQ ID NO:
- 18] (28C5 H-CDR3);
- and
- (iii) an antibody that comprises:
- a) an antibody VL domain, or antigen binding fragment thereof, comprising L-CDR1, L-CDR2 and L-CDR3, wherein:
- L-CDR1 comprises the sequence RASQDIKNYLN [SEQ ID NO:
- 19] (18E12 L-CDR1);
- L-CDR2 comprises the sequence YTSRLHS [SEQ ID NO:
- 20] (18E12 L-CDR2);
- and L-CDR3 comprises the sequence QRGDTLPWT [SEQ ID NO:
- 21] (18E12 L-CDR3);
- and b) an antibody VH domain, or antigen binding fragment thereof, comprising H-CDR1, H-CDR2 and H-CDR3, wherein:
- H-CDR1 comprises the sequence NYDIS [SEQ ID NO:
- 22] (18E12 H-CDR1);
- H-CDR2 comprises the sequence VIWTSGGTNYNSAFMS [SEQ ID NO:
- 23] (18E12 H-CDR2);
- and H-CDR3 comprises the sequence GDGNFYLYNFDY [SEQ ID NO:
- 24] (18E12 H-CDR3).
Dependencies are inferred from the claim text.